Advantage Alpha Capital Partners LP Acquires New Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Advantage Alpha Capital Partners LP acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,289 shares of the company’s stock, valued at approximately $417,000.

A number of other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the period. Jamison Private Wealth Management Inc. purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth $28,000. Key Financial Inc bought a new position in shares of Krystal Biotech during the 2nd quarter worth $28,000. Blue Trust Inc. grew its position in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Krystal Biotech during the third quarter valued at $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Stock Up 1.0 %

NASDAQ:KRYS opened at $196.52 on Wednesday. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of 111.03 and a beta of 0.82. Krystal Biotech, Inc. has a 52 week low of $99.00 and a 52 week high of $219.34. The firm has a 50 day moving average of $179.69 and a 200 day moving average of $183.09.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the prior year, the business posted ($0.67) EPS. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. As a group, analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KRYS. Evercore ISI increased their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Tuesday, November 5th. Finally, Chardan Capital lifted their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).